Monte Rosa Therapeutics (GLUE) Cash from Financing Activities (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Cash from Financing Activities of $328.3 million for Q1 2026, up 2345150.0% year-over-year from N/an in Q1 2025, and up 1008.34% quarter-over-quarter from $29.6 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $328.3 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 2345150.0% year-over-year to $328.3 million; the TTM figure through Mar 2026 stood at $358.7 million (up 263.54% YoY), while the FY2025 annual figure was $30.4 million, down 69.31% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $328.3 million, up from $29.6 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $328.3 million in Q1 2026, with the low at -$217000.0 in Q3 2022.
- The 5-year median for Cash from Financing Activities is $365000.0 (2025), against an average of $29.7 million.
- The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities sank 100.74% in 2022, then soared 2345150.0% in 2026.
- Monte Rosa Therapeutics' Cash from Financing Activities stood at $20.4 million in 2022, then increased by 23.19% to $25.2 million in 2023, then tumbled by 97.58% to $608000.0 in 2024, then jumped by 4772.37% to $29.6 million in 2025, then soared by 1008.34% to $328.3 million in 2026.
- Business Quant data shows GLUE's Cash from Financing Activities at $328.3 million in Q1 2026, $29.6 million in Q4 2025, and $348000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | 3.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.21 Mn |
| Jun 30, 2026 | 3.21 Mn |
| Mar 31, 2026 | 328.34 Mn |
| Mar 31, 2026 | 328.34 Mn |
| Dec 31, 2025 | 29.62 Mn |
| Dec 31, 2025 | 29.62 Mn |
| Sep 30, 2025 | 348,000.00 |
| Sep 30, 2025 | 348,000.00 |
| Jun 30, 2025 | 365,000.00 |
| Jun 30, 2025 | 365,000.00 |
| Mar 31, 2025 | 14,000.00 |
| Mar 31, 2025 | 14,000.00 |
| Dec 31, 2024 | 608,000.00 |
| Dec 31, 2024 | 608,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Jun 30, 2024 | 98.02 Mn |
| Jun 30, 2024 | 98.02 Mn |
| Mar 31, 2024 | 246,000.00 |
| Mar 31, 2024 | 246,000.00 |